8,306 Shares in Disc Medicine, Inc. $IRON Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D purchased a new stake in Disc Medicine, Inc. (NASDAQ:IRON) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,306 shares of the company’s stock, valued at approximately $660,000.

Several other large investors have also bought and sold shares of the stock. Assenagon Asset Management S.A. grew its stake in shares of Disc Medicine by 3,329.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock worth $28,416,000 after acquiring an additional 347,403 shares in the last quarter. TimesSquare Capital Management LLC bought a new position in shares of Disc Medicine during the third quarter valued at about $12,038,000. Y Intercept Hong Kong Ltd boosted its holdings in Disc Medicine by 361.4% during the third quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock worth $2,860,000 after purchasing an additional 33,905 shares during the last quarter. Atle Fund Management AB grew its position in Disc Medicine by 85.3% in the 3rd quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock worth $3,019,000 after purchasing an additional 21,038 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in Disc Medicine in the 3rd quarter worth about $6,752,000. 83.70% of the stock is currently owned by institutional investors.

Insider Activity at Disc Medicine

In related news, COO Jonathan Yen-Wen Yu sold 3,231 shares of Disc Medicine stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $203,100.66. Following the completion of the sale, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $3,414,806.64. This trade represents a 5.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider William Jacob Savage sold 7,378 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $65.88, for a total value of $486,062.64. Following the completion of the sale, the insider owned 85,211 shares in the company, valued at $5,613,700.68. This represents a 7.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 59,410 shares of company stock worth $3,840,013 in the last three months. Corporate insiders own 3.76% of the company’s stock.

Wall Street Analysts Forecast Growth

IRON has been the topic of several recent analyst reports. Cantor Fitzgerald dropped their target price on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. BMO Capital Markets decreased their price target on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research report on Tuesday, February 17th. Wedbush dropped their price target on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a report on Tuesday, February 17th. Finally, Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $104.80.

Disc Medicine Trading Up 1.4%

Shares of IRON stock opened at $69.23 on Tuesday. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.64 billion, a P/E ratio of -10.46 and a beta of 0.93. The company has a 50 day moving average of $65.09 and a 200-day moving average of $75.68. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). Sell-side analysts anticipate that Disc Medicine, Inc. will post -6.77 earnings per share for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.